Q-omics provides the consensus-scored INMT-MINDY4 profile across patient tissues and cancer cell-line models. INMT-MINDY4 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, INMT-MINDY4 is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, INMT-MINDY4 RNA expression shows 12,395 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight DLBC, LUAD, and THYM as cancer lineages where INMT-MINDY4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INMT-MINDY4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INMT-MINDY4 survival associations across molecular data types. INMT-MINDY4 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INMT-MINDY4 RNA expression–survival associations across cancer types. High INMT-MINDY4 expression shows unfavorable associations in DLBC, UCEC and KIRP, but favorable associations in LUAD, MESO and CHOL. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for INMT-MINDY4 RNA expression.
This table summarizes INMT-MINDY4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for INMT-MINDY4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INMT-MINDY4 shows lower tumor expression in LUAD, BLCA, LUSC, KICH, UCEC and BRCA. The LUAD box plot shows higher INMT-MINDY4 RNA expression in normal versus tumor tissue (log2 FC = −0.648, t-test p < 0.001).
This table shows molecular features associated with INMT-MINDY4 in patient tissues and cancer cell lines. In patient samples, INMT-MINDY4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, INMT-MINDY4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY.
